MR Vaccines Market

Measles and rubella is a live virus vaccine that protects against infection with the measles and rubella viruses. It works by causing the body to produce its antiviral defenses (antibodies). Measles (also known as coughing measles, hard measles, morbilli, red measles, rubeola, and 10-day measles) is a highly contagious infectious disease. Measles infection can result in significant complications such as pneumonia, ear infections, sinus infections, convulsions (seizures), brain damage, and death. Adults and children under the age of 5 years are at a higher risk of serious complications and mortality. When pregnant women contract rubella (also known as German measles), it can result in miscarriages, stillbirths, or birth abnormalities in their unborn children. Market Dynamics Measles and Rubella (MR) vaccine is a subcutaneous injection for active immunization against Measles and Rubella in young adults, adolescents, children, and infants at risk. Increasing incidence of Measles and Rubella (MR), ongoing clinical trials to develop MR vaccines, growing awareness about immunization services, rising government initiatives to launch vaccine campaigns, and increasing adoption of inorganic growth strategies such partnerships by key players operating in the MR vaccines market with organizations such as WHO, UNICEF, and the GAVI Alliance are the major factors that are expected to drive growth of the MR vaccines market over the forecast period. For instance, according to the World Health Organization (WHO), from January 2020 to April 2021, eight African nations experienced major measles outbreaks that affected tens of thousands of children, owing to delayed vaccination programs or low routine immunization coverage. Key features of the study • This report provides an in-depth analysis of the MR vaccines market, and provides market size (US$ Mn. and No. of Doses in Mn.), and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the MR vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans • Key companies covered as a part of this study include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The MR vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the MR vaccines market Market Segmentation • By Vaccine Brand o MR Vaccine o MRBEV (BE LTD.) • By Distribution Channel o Public o Private • By Region o Commonwealth of Independent States (CIS) Countries  Russia  Uzbekistan  Kazakhstan  Ukraine  Turkmenistan  Belarus  Armenia o Latin America  Brazil  Argentina  Mexico  Honduras  Colombia  Peru  Chile o Europe  Turkey o Asia Pacific  Pakistan  Indonesia  Bangladesh  Philippines  Vietnam  Thailand  Myanmar  Malaysia  Cambodia  Nepal  Sri Lanka  Papua New Guinea  Mauritius o Middle East  Israel  UAE  Iraq  Iran  Saudi Arabia  Jordan  Qatar  Oman  Syrian Arab Republic o Africa  South Africa  Nigeria  Tanzania  Democratic Republic of Congo  Ethiopia  Kenya  Egypt  Morocco  Ghana  Uganda  Burkina Faso  Angola  Algeria  Zimbabwe  Tunisia  Botswana  Libya  Namibia • Key Players o PT Bio Farma o Bio-Manguinhos o BE Vaccines o Serum Institute of India o Crucell Switzerland AG